Skip to main
ALMS

Alumis Inc (ALMS) Stock Forecast & Price Target

Alumis Inc (ALMS) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alumis Inc. showcases a promising outlook due to its innovative pipeline, particularly the potential of envudeucitinib (envu), which is positioned favorably compared to current market leaders like Takeda's treatments. The company's focus on precision medicine and targeted therapies aims to revolutionize treatment modalities for autoimmune disorders, which could translate into significant market opportunities. With favorable cost of goods sold (COGS) metrics and improvements anticipated in key efficacy criteria, Alumis is strategically positioned to become a leader in the TYK2 inhibitor segment, enhancing its growth potential and value proposition in the biopharmaceutical landscape.

Bears say

Alumis Inc faces significant uncertainties regarding the efficacy and timely advancement of its clinical programs, particularly concerning ESK-001 and envu, which could adversely affect commercialization and regulatory approval timelines. The reported efficacy plateau of rival products, as demonstrated by Takeda’s zasuticinib, raises questions regarding the competitive positioning of Alumis's pipeline, suggesting potential challenges in achieving market uptake. Additionally, the company’s current estimated enterprise value of approximately $730 million may not adequately reflect the increased risks of regulatory delays, competitive threats, and possible dilution, contributing to a negative outlook on its stock.

Alumis Inc (ALMS) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alumis Inc (ALMS) Forecast

Analysts have given Alumis Inc (ALMS) a Buy based on their latest research and market trends.

According to 5 analysts, Alumis Inc (ALMS) has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alumis Inc (ALMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.